Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Advanced Enzyme Technologies EBITDA Margin % Related Terms
Advanced Enzyme Technologies EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ADVENZYMES vs LIN, SHW, ECL: EBITDA Margin % Comparison
For the Specialty Chemicals subindustry, Advanced Enzyme Technologies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Enzyme Technologies EBITDA Margin % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Advanced Enzyme Technologies's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Advanced Enzyme Technologies's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Enzyme Technologies (NSE:ADVENZYMES) has a EBITDA Margin % of 34.70% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Advanced Enzyme Technologies and its competitors. This is 14% below median its historical median of 40.53. Over the past decade, Advanced Enzyme Technologies' EBITDA Margin % has ranged from 32.91 to 48.05. According to the industry distribution chart, Advanced Enzyme Technologies ranks #54 out of 1579 companies in the Chemicals industry, placing it in the top 3.4%.
Is Advanced Enzyme Technologies' EBITDA Margin % too high?
Advanced Enzyme Technologies' current EBITDA Margin % of 34.70% is 14% below median its 10-year median of 40.53. Over the past 10 years, this metric has ranged from a low of 32.91 to a high of 48.05. The Chemicals industry median EBITDA Margin % is 9.70. Advanced Enzyme Technologies' value of 34.70% is 257.7% above this industry median. Based on the distribution chart, Advanced Enzyme Technologies ranks #54 out of 1579 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, Advanced Enzyme Technologies has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Advanced Enzyme Technologies' EBITDA Margin % compare to LIN and SHW?
According to the Chemicals industry distribution chart, Advanced Enzyme Technologies ranks #54 out of 1579 companies for EBITDA Margin %. This places Advanced Enzyme Technologies in the top 3% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 9.70. Advanced Enzyme Technologies' value of 34.70% is 257.7% above this benchmark. Historically, Advanced Enzyme Technologies' own EBITDA Margin % has ranged from 32.91 to 48.05 over the past decade. While the company's 10-year median is 40.53 vs. the industry median of 9.70, Advanced Enzyme Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Chemicals company?
The median EBITDA Margin % among Chemicals companies is 9.70, based on 1,579 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Advanced Enzyme Technologies's current EBITDA Margin % of 34.70% is 257.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Advanced Enzyme Technologies and its competitors. For the Chemicals industry, the median EBITDA Margin % is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Enzyme Technologies's current EBITDA Margin % is 34.70%, which is 14% below median its own 10-year median of 40.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Enzyme Technologies stock overvalued right now?
Based on GuruFocus' analysis, Advanced Enzyme Technologies (NSE:ADVENZYMES) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹420.89, compared to a current price of ₹324.35 — trading 22.9% below its estimated fair value. The current EBITDA Margin % is 34.70%, which is 14% below median its 10-year median of 40.53 and 257.7% above the Chemicals industry median of 9.70. Advanced Enzyme Technologies' overall GF Score™ is 89/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Advanced Enzyme Technologies (NSE:ADVENZYMES), the current EBITDA Margin % is 34.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Advanced Enzyme Technologies (NSE:ADVENZYMES) Overvalued in 2026?
Based on GuruFocus' analysis, Advanced Enzyme Technologies stock appears to be undervalued.
The current stock price of ₹324.35 is trading 22.9% below its estimated GF Value™ of ₹420.89.
GuruFocus considers Advanced Enzyme Technologies to be Modestly Undervalued.
Key valuation signals for NSE:ADVENZYMES:
EBITDA Margin %: 34.70% (14% below median its 10-year median of 40.53)
GF Value™: ₹420.89 vs. price of ₹324.35 (22.9% below fair value)
Industry Position: 257.7% above the Chemicals median (#54 of 1579)
No single metric tells the full story. See the NSE:ADVENZYMES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Advanced Enzyme Technologies Ltd is an Indian company engaged in research activities to manufacture and sell enzymes. The company operates only in one business segment, viz., manufacturing and sales of enzymes. The company offers enzymes for human healthcare and nutrition, animal nutrition, food processing, and non-food processing. Some of the products offered by the company are serratiopeptidase, fungal lipase, papain, hemicellulose, and digegrain, among others. Geographically, the entity operates in India, Europe, the USA, Asia, and other countries, of which a majority of the revenue is derived from India.
89GF Score
Get the complete analysis for NSE:ADVENZYMES
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ADVENZYMES has been successfully added to your 
